fda approves first oral glp-1 obesity drug august 1 2025 Grants Speedy Approval to Eli Lilly's RA for FDA Approves Wegovy Weight-Loss Pill

If the preclinical data translate to the clinic, amylin has a good chance to supplant GLP-1 for the overweight to moderate obesity population March 7, 2025 8:46 PM UTC Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking scores

16.0% placebo)

Try our new Rash and Skin Condition Finder

At Vie Aesthetics, we often suggest moving beyond simple injections to more advanced, medical-grade technologies that treat both fat volume and skin integrity simultaneously

These compounds are typically employed for their growth hormone-releasing properties, yet recent research indicates a compelling secondary benefit: the indirect enhancement of hair follicle activity via increased insulin-like growth factor 1 (IGF-1) availability

Stromal cell-derived factor-1/Exendin-4 cotherapy facilitates the proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells in vitro and promotes periodontal bone regeneration in vivo